Abzena company developed a series of antibody drug conjugates (ADCs) using IgG1, IgG2, IgG4, mAbs, and other antibodies modified with proprietary ThioBridge® technology (WO 2017/199046) to couple covalently both the drug and the cyclodextrin. The obtained stabile and site-specific drug delivery system successfully reduced the tumor size in various mouse tumor models achieveing 100% cancer-free status in certain cases.
Antibody conjugated cyclodextrin for tumor drug delivery
Posted by